Mutations

SORL1 Y391C

Overview

Clinical Phenotype: Alzheimer's Disease
Position: (GRCh38/hg38):Chr11:121514282 A>G
Position: (GRCh37/hg19):Chr11:121384991 A>G
dbSNP ID: rs139710266
Coding/Non-Coding: Coding
DNA Change: Substitution
Expected Protein Consequence: Missense
Codon Change: TAT to TGT
Reference Isoform: SORL1 Isoform 1 (2214 aa)
Genomic Region: Exon 8

Findings

In a study that included 15,808 Alzheimer’s cases and 16,097 control subjects from multiple European and American cohorts, this allele was observed 12 times among the AD cases and was absent from the controls (Holstege et al., 2022). However, due to the small number of carriers, mega-analysis of these data did not show an association between the variant and AD risk. The Alzheimer Disease Exome Sequencing France (ADESFR) project, the Alzheimer’s Disease Sequencing Project (ADSP), and a Dutch sample reported by Holstege et al. (Holstege et al., 2017) all contributed data to the mega-analysis.

In another dataset from subjects of European-American ancestry, this variant was found with minor allele frequencies of 1.16×10-3 and 1.54×10-3 in cases and controls, respectively, and it did not associate with disease (Fernández et al., 2016).

This variant is classified as likely benign by the criteria of Holstege et al. (Holstege et al., 2017).

Functional Consequences

Tyrosine-391 is found within a loop structure that connects the sixth and seventh Vps10p β-propellers. This loop structure is thought to be critical for peptide binding to SORL1, and changes in the conformation of the loop structure at acidic pH may underlie the release of peptide ligands in lysosomes (Kitago et al., 2015). Mutations resulting in a gain of a cysteine within the loop structure likely disrupt the conformation of the structure, and Andersen and colleagues have predicted that such mutations at this position are highly likely to associate with AD risk (Andersen et al., 2023).

The Y391C variant was predicted to be tolerated by SIFT but deleterious by Mutation Taster and PolyPhen-2 (Campion et al., 2019).

Table

Risk Allele(s) N
Cases | Controls
aAllele frequency
Cases | Controls
Reported association measurements Ancestry
(Cohort)
Reference(s)
Large-scale studies, meta- and mega-analyses
G 15,808 | 16,097 7.80×10-4 | 0 p = 0.89 Multiple European and American cohorts Holstege et al., 2022
(mega-analysis)
Other studies
G  852 (EOAD) | 927 (LOAD) | 1273 (CTRL) 5.87×10-4 | 0 | 0   French
(Alzheimer Disease Exome Sequencing France (ADESFR))
Bellenguez et al., 2017; Campion et al., 2019
G 5198 | 4491 3.85×10-4 | 0   Non-Hispanic Caucasian
(Alzheimer’s Disease Sequencing Project (ADSP))
Campion et al., 2019
G familial LOAD
875 | 328
1.16×10-3 | 1.54×10-3 OR = 0.748
[CI: N.A.]
Reported not significant
European American
(Knight ADRC, NIA-LOAD)
Fernández et al., 2016
G 640 | 1268 7.81×10-4 | 0   Dutch
(Rotterdam Study, Amsterdam Dementia Cohort, Alzheimer Centrum Zuidwest Nederland (ACZN), 100-plus Study)
Holstege et al., 2017
G 332 | 676 0 | 0   UK and North American Caucasian
(NIH-UCL, Knight ADRC, ADNI, Cache County Study on Memory in Aging)
Sassi et al., 2016;
Campion et al., 2019
G 1255 | 1938 0 | 0   European
(European Early-Onset Dementia Consortium)
Verheijen et al., 2016; Campion et al., 2019

aAllele frequencies as reported by study authors or calculated by Alzforum curators from data provided in the study, assuming heterozygosity if not explicitly stated in the paper.

This table is meant to convey the range of results reported in the literature. As specific analyses, including co-variates, differ among studies, this information is not intended to be used for quantitative comparisons, and readers are encouraged to refer to the original papers. Thresholds for statistical significance were defined by the authors of each study. (Significant results are in bold.) Note that data from some cohorts may have contributed to multiple studies, so each row does not necessarily represent an independent dataset. While every effort was made to be accurate, readers should confirm any values that are critical for their applications.

Last Updated: 18 Jul 2024

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Paper Citations

  1. . Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease. Nat Genet. 2022 Dec;54(12):1786-1794. Epub 2022 Nov 21 PubMed.
  2. . Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. Eur J Hum Genet. 2017 Aug;25(8):973-981. Epub 2017 May 24 PubMed.
  3. . SORL1 variants across Alzheimer's disease European American cohorts. Eur J Hum Genet. 2016 Dec;24(12):1828-1830. Epub 2016 Sep 21 PubMed.
  4. . Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiol Aging. 2017 Nov;59:220.e1-220.e9. Epub 2017 Jul 14 PubMed.
  5. . SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data. Acta Neuropathol. 2019 Aug;138(2):173-186. Epub 2019 Mar 25 PubMed.
  6. . Influence of Coding Variability in APP-Aβ Metabolism Genes in Sporadic Alzheimer's Disease. PLoS One. 2016;11(6):e0150079. Epub 2016 Jun 1 PubMed.
  7. . A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. Acta Neuropathol. 2016 Aug;132(2):213-24. Epub 2016 Mar 30 PubMed.
  8. . Structural basis for amyloidogenic peptide recognition by sorLA. Nat Struct Mol Biol. 2015 Mar;22(3):199-206. Epub 2015 Feb 2 PubMed.
  9. . Relying on the relationship with known disease-causing variants in homologous proteins to predict pathogenicity of SORL1 variants in Alzheimer's disease. 2023 Feb 27 10.1101/2023.02.27.524103 (version 1) bioRxiv.

Further Reading

No Available Further Reading

Protein Diagram

Primary Papers

  1. . SORL1 variants across Alzheimer's disease European American cohorts. Eur J Hum Genet. 2016 Dec;24(12):1828-1830. Epub 2016 Sep 21 PubMed.

Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.